Zobrazeno 1 - 4
of 4
pro vyhledávání: '"T. M. Mohiuddin"'
Autor:
Kenan A. J. Bozhüyük, Leonard Präve, Carsten Kegler, Sebastian Kaiser, Yan-Ni Shi, Wolfgang Kuttenlochner, Leonie Schenk, T. M. Mohiuddin, Michael Groll, Georg K. A. Hochberg, Helge B. Bode
Many clinically used drugs are derived from or inspired by bacterial natural products that often are biosynthesised via non-ribosomal peptide synthetases (NRPS), giant megasynthases that activate and join individual amino acids in an assembly line fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::370c2b7733fadbf661a3aaac117a0b5c
https://doi.org/10.1101/2022.12.02.518901
https://doi.org/10.1101/2022.12.02.518901
Autor:
Wenjie Sheng, Chaoyu Zhang, T. M. Mohiuddin, Marwah Al-Rawe, Felix Zeppernick, Franco H. Falcone, Ivo Meinhold-Heerlein, Ahmad Fawzi Hussain
Publikováno v:
International Journal of Molecular Sciences. 24:3086
Traditional immunohistochemistry (IHC) has already become an essential method of diagnosis and therapy in cancer management. However, this antibody-based technique is limited to detecting a single marker per tissue section. Since immunotherapy has re
Autor:
T. M. Mohiuddin, Chaoyu Zhang, Wenjie Sheng, Marwah Al-Rawe, Felix Zeppernick, Ivo Meinhold-Heerlein, Ahmad Fawzi Hussain
Publikováno v:
International Journal of Molecular Sciences. 24:2655
Near infrared photoimmunotherapy (NIR-PIT) is a newly developed molecular targeted cancer treatment, which selectively kills cancer cells or immune-regulatory cells and induces therapeutic host immune responses by administrating a cancer targeting mo
Autor:
Chaoyu, Zhang, Wenjie, Sheng, Marwah, Al-Rawe, T M, Mohiuddin, Marcus, Niebert, Felix, Zeppernick, Ivo, Meihold-Heerlein, Ahmad Fawzi, Hussain
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 11; Pages: 6122
Triple-negative breast cancer (TNBC) is a group of heterogeneous and refractory breast cancers with the absence of estrogen receptor (ER), progesterone receptor (PgR) and epidermal growth factor receptor 2 (HER2). Over the past decade, antibody drug